Physician profile
Terry D Guiley
NPI 1639183320
$3,791.60
in general payments reported to CMS, 2019-2025
22 companies · $504 in 2025
The $504 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $649 · 2020: $365 · 2021: $799 · 2022: $520 · 2023: $414 · 2024: $541 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,414 · Education: $45.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,413.82 |
| Education | $45.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $585.28 | 2022-2025 | Azstarys |
| Avanir Pharmaceuticals, INC. | $454.74 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $421.62 | 2019-2022 | |
| Abbvie INC. | $359.40 | 2021-2025 | |
| Axsome Therapeutics, INC. | $353.25 | 2022-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $345.29 | 2019-2020 | |
| Harmony Biosciences LLC | $247.79 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $176.41 | 2019-2021 | |
| Allergan, INC. | $157.00 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $130.95 | 2019-2025 | Rexulti |
| Eisai INC. | $128.39 | 2020-2021 | |
| Alkermes, INC. | $102.49 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Takeda Pharmaceuticals U.S.A., INC. | $100.32 | 2023-2025 | Trintellix |
| Lundbeck LLC | $59.45 | 2021-2024 | Rexulti |
| Collegium Pharmaceutical, INC. | $44.47 | 2025 | Jornay Pm |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $26.79 | 2024 | Xelstrym |
| Adlon Therapeutics L.P. | $19.56 | 2021 | |
| Jazz Pharmaceuticals INC. | $18.74 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.14 | 2025 | Caplyta |
| Vertical Pharmaceuticals, LLC | $15.85 | 2025 | Relexxii |
| Grifols USA, LLC | $14.92 | 2022 | |
| Indivior INC. | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Guiley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.